Ethypharm - About us - At a glance
At a glance

A clear focus on CNS and Critical care

Ethypharm is a specialty pharmaceutical company with prominent products in targeted central nervous system (CNS) indications, notably severe pain, and opioid dependency as well as a wide range of high-quality injectable medicines for critical care situations.

To continue on our transformation journey and accelerate our growth, we have identified specific CNS diseases and conditions and critical care situations where our skills and know-how can be leveraged to bring innovations to patients and health care providers.
Our teams and resources are fully focused on making these opportunities happen.

A resilient company

The ongoing COVID-19 pandemic has put significant pressure on the pharmaceutical industry.

At Ethypharm, this crisis has highlighted the major role of our Critical Care products, which have been in high demand in intensive care units (ICU), as well as our CNS products related to mental health and addictive disorders.

Our manufacturing, quality, supply chain and commercial teams have put in tremendous efforts since the pandemic outbreak to ensure the continuous supply of our medicines in all of our markets.

A committed, diverse, and experienced management team

Ethypharm is about people first. We care deeply about our employees and are proud of the diversity of talents we have internationally.

The Group is led by a 12-member Executive Committee which, together, equals over a couple of hundred years of experience in the pharmaceutical industry, across companies of various size and specialties.

An entrepreneurial mindset and shared values knits us together to achieve our vision for the Group.

Discover our Executive committee

A solid and growing presence in our core geographies

Since 2015, Ethypharm has built, and is rapidly expanding, its direct commercial presence in Europe and China.

Europe, where we currently have 3 affiliates covering the 3 largest markets – Germany, France, and the United Kingdom – accounts for half of the Group’s net sales. We are actively working on expanding our presence to gain greater EU5 coverage.

In China, Ethypharm is one among the few European specialty pharmaceutical companies to have a longstanding direct presence. This great asset is being leveraged, via partnerships, to bring orphan medicines, that are already registered in other geographies, to patients in China.

In the rest of the world, we rely on our network of commercial partners to establish and develop the reach of our product portfolio.

Ethypharm key figures (2019)

334 M€
Group net sales
in CNS and Critical Care

direct countries

of direct revenues

manufacturing sites